Trial Profile

A Randomized Phase 2 Trial to Evaluate the Efficacy of BCL-2 Inhibitor Therapy With Chemotherapy Compared to Chemotherapy Alone in Adult Patients With Newly Diagnosed T-Cell ALL and T-Cell Lymphoblastic Lymphoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 14 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Calaspargase pegol (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Mercaptopurine (Primary) ; Methotrexate (Primary) ; Nelarabine (Primary) ; Pegaspargase (Primary) ; Tioguanine (Primary) ; Vincristine (Primary)
Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use

07 May 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
24 Apr 2024 Planned initiation date changed from 18 Apr 2024 to 9 Aug 2024.
22 Jan 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com